Mangoceuticals Q2 2026: Cash Drops to $229K, Going Concern Warning Reiterated, Nuclea Reverse Merger Details Emerge
MGRX has more than doubled off its 52-week low of $0.162 on elevated volume (1.9× avg).
Summary
Mangoceuticals' Q2 2026 10-Q shows cash down to $229K, a reiterated going concern warning, Nasdaq delisting risk, and detailed terms of the Nuclea Energy reverse merger that will leave existing holders with just 4% of the combined company.
Key Events · Earnings and Guidance · MGRX
-
Cash Collapses to $229K
Cash and cash equivalents fell from $1,486,338 at December 31, 2025 to $228,688 at June 30, 2026, a decline of $1,257,650 in six months.
-
Going Concern Warning Reiterated
Management states substantial doubt about the company's ability to continue as a going concern and that it is unlikely to meet funding requirements over the next 12 months without additional financing.
-
Revenue Declines 59%
Q2 2026 revenue was $68,757 versus $168,109 in Q2 2025, a 59% decrease, while net loss was $1,312,931 compared to $5,415,820 a year earlier.
-
Nasdaq Delisting Risk
The company remains non-compliant with Nasdaq's $1.00 minimum bid price rule and has until February 1, 2027 to regain compliance, with a reverse stock split possible.
Analysis · MGRX · Industrial Applications And Services
The Q2 2026 10-Q from Mangoceuticals confirms a deteriorating financial position: cash fell from $1.49M to $229K in six months, revenue collapsed 59% year-over-year to $68,757, and the accumulated deficit reached $45.4M. Management reiterates substantial doubt about the company's ability to continue as a going concern, stating it is unlikely to meet funding requirements over the next 12 months without additional financing. The filing also discloses the company remains non-compliant with Nasdaq's $1.00 minimum bid price rule, with a compliance deadline of February 1, 2027. Critically, the 10-Q provides the first detailed financial statement disclosure of the July 29, 2026 Business Combination Agreement with Nuclea Energy, including the 96%/4% ownership split, the $15M PIPE financing condition, and CEO Jacob Cohen's $1.5M cash severance plus 2M bonus shares and a $10M Mango & Peaches warrant. For existing shareholders, this filing quantifies both the near-term liquidity crisis and the extreme dilution embedded in the pending reverse merger.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGRX was trading at $0.63 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $0.16 to $2.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.